FDA批准诺华旗下Ilaris用于治疗儿童关节炎

2013-05-14 FDA dxy

5月10日,诺华表示美国食品药品管理局(FDA)批准该公司用于治疗严重型儿童关节炎的药物Ilaris。诺华声称,Ilaris是一种全人源化单克隆抗体,能够靶向阻断白细胞介素-1β,白细胞介素-1β的过度产生在某些炎性疾病中扮演重要角色角色。Ilaris可每月皮下注射一次,是目前唯一一个被批准用来治疗该种疾病的药物。Ilaris还在欧盟被批准用于治疗难治性痛风性关节炎。与关节炎相关的拓展阅读:OAR

5月10日,诺华表示美国食品药品管理局(FDA)批准该公司用于治疗严重型儿童关节炎的药物Ilaris。
诺华声称,Ilaris是一种全人源化单克隆抗体,能够靶向阻断白细胞介素-1β,白细胞介素-1β的过度产生在某些炎性疾病中扮演重要角色角色。Ilaris可每月皮下注射一次,是目前唯一一个被批准用来治疗该种疾病的药物。Ilaris还在欧盟被批准用于治疗难治性痛风性关节炎。
关节炎相关的拓展阅读:


U.S. approves Novartis drug Ilaris to treat childhood arthritis
Novartis said on Friday the U.S. Food and Drug Administration (FDA) had approved its drug Ilaris to treat a serious form of childhood arthritis.
Ilaris inhibits interleukin-1 beta, excessive production of which plays a prominent role in certain inflammatory diseases, the company said.
The drug is the only approved treatment specifically for the condition that can be given as a monthly subcutaneous injection, Novartis said.
Ilaris is also approved in the European Union for the treatment of refractory gouty arthritis, Novartis said.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839225, encodeId=e0b518392251f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Mar 25 16:07:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003300, encodeId=7614200330062, content=<a href='/topic/show?id=77569e1855' target=_blank style='color:#2F92EE;'>#Ilaris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9718, encryptionId=77569e1855, topicName=Ilaris)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Apr 06 12:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265134, encodeId=2eaa126513465, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu May 16 05:07:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282603, encodeId=67a7128260374, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu May 16 05:07:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]
    2014-03-25 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839225, encodeId=e0b518392251f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Mar 25 16:07:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003300, encodeId=7614200330062, content=<a href='/topic/show?id=77569e1855' target=_blank style='color:#2F92EE;'>#Ilaris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9718, encryptionId=77569e1855, topicName=Ilaris)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Apr 06 12:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265134, encodeId=2eaa126513465, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu May 16 05:07:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282603, encodeId=67a7128260374, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu May 16 05:07:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]
    2014-04-06 xzw113
  3. [GetPortalCommentsPageByObjectIdResponse(id=1839225, encodeId=e0b518392251f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Mar 25 16:07:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003300, encodeId=7614200330062, content=<a href='/topic/show?id=77569e1855' target=_blank style='color:#2F92EE;'>#Ilaris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9718, encryptionId=77569e1855, topicName=Ilaris)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Apr 06 12:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265134, encodeId=2eaa126513465, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu May 16 05:07:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282603, encodeId=67a7128260374, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu May 16 05:07:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]
    2013-05-16 lmm397
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839225, encodeId=e0b518392251f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Mar 25 16:07:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003300, encodeId=7614200330062, content=<a href='/topic/show?id=77569e1855' target=_blank style='color:#2F92EE;'>#Ilaris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9718, encryptionId=77569e1855, topicName=Ilaris)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Apr 06 12:07:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265134, encodeId=2eaa126513465, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Thu May 16 05:07:00 CST 2013, time=2013-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282603, encodeId=67a7128260374, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu May 16 05:07:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]

相关资讯

FDA批准Tecfidera治疗多发性硬化症

  美国食品药品管理局(FDA)已批准一种新的每日2次口服药物——富马酸二甲酯用于治疗复发缓解型多发性硬化症(RRMS)。   将以Tecfidera作为商品名上市的该药物被认为具有预防大脑氧化应激的作用。此外,试验证据表明,它还具有抗炎和神经保护剂的作用。   Tecfidera将成为众多已获批的MS治疗药物之一。根据美国多发性硬化症学会(NMSS)资料,两种剂型的干扰素β-1a(Avone

雅培生命旗下丙肝复方药物获FDA突破性治疗药物资格

5月6日,雅培生命表示美国食品药品管理局(FDA)授予其抗丙肝病毒复方药物突破性治疗药物资格,该资格的获得将有助于加快这一复方药物的审评进度,或许还能缩短其临床试验过程。 雅培生命的这款复方药物由ABT-450/r(蛋白酶抑制剂和利托那韦)、ABT-267(NS5A抑制剂)和ABT-333(非核苷聚合酶抑制剂)组成,此外还可加或不加利巴韦林。其突破性治疗药物资格是紧继吉利德的Sofosbuvir

FDA咨询委员会建议终止鲑降钙素销售

    3月6日,FDA咨询委员会专家建议,终止在绝经5年以上女性中应用鲑降钙素治疗骨质疏松。  由于获益缺乏以及潜在癌症风险,FDA生殖健康药物及药物安全和风险管理咨询委员会以12比9的投票结果建议终止降钙素鼻喷剂销售。鲑降钙素可增加骨骼中钙含量并降低血钙水平。因鲑降钙素鼻喷剂应用者的癌症形成风险较未应用者升高2.4%,欧洲药品管理局(EMA)于2012年建议鲑降钙

REUTERS:FDA对怀孕期间使用丙戊酸钠类药物发出警告

美国食品药品管理局(FDA)对孕妇使用偏头痛药物丙戊酸钠发布警告,指出丙戊酸钠可导致婴儿智商降低。FDA表示,最近的研究结果显示,在子宫中接触过丙戊酸钠产品的六岁儿童相比接触其它抗癫痫药的儿童其智商相对较低。含有丙戊酸钠的药物被用来预防偏头痛,治疗癫痫以及与躁郁症相关的躁狂发作。丙戊酸钠以商品名Depacon上市,双丙戊酸钠以商品名Depakote、Depakote CP、Depakote ER上

默沙东黑色素瘤药物Lambrolizumab获FDA“突破性疗法”资格

    黑色素瘤通常与过度暴露于紫外线有关,根据美国国家癌症研究所的数据,2013年美国预期会出现76690新病例,其中9480名患者会因此死亡。    突破性疗法资格的获得使lambrolizumab(代号 MK-3475)引起众人关注,授予lambrolizumab这一资格意味着FDA认可该治疗药物对威胁生命的疾病表现出明显收益,而且

FDA拟重新审议GSK糖尿病药物文迪雅的安全性

     美国联邦卫生顾问小组将于6月份对葛兰素史克旗下糖尿病药物文迪雅(Avandia)的安全性数据予以重新审议,尽管GSK于近日声称,它已不再寻求使之广泛应用于临床。     010年9月份,美国食品药品管理局(FDA)出于对文迪雅心脏病发作和死亡有关的安全性考虑,对该产品的使用设置了严重限制,只允许文迪雅